Low carbohydrate diet research by glucose variability with various medical care such as physiotherapy and music therapy

Abstract

Background: DM type-2 is characterized by gradual decrease in insulin sensitivity within the peripheral tissues and liver (insulin resistance), followed by gradual decline in β-cell function and insulin secretion. Thus, patients with poor glycemic control require the utilization of insulin therapy to realize the target of yank Diabetes Association, recommending HbA1c to be but 7% (≥8% despite of optimal doses of anti-diabetic drugs). Aim: This study aimed to guage and addressing the barriers to be used of insulin in type-2 DM patients, where their glycemic control is poor, i.e., HbA1c is ≥8% despite of optimal doses of anti-diabetic drugs. Research Design & Method: We surveyed 200 patients with type-2 diabetes mellitus, i.e., cross-sectional quantitative study; patients showed poor glycemic control HbA1c≥8%, already treated with one or more oral agents, who recently prescribed insulin to regulate their metabolic status. Data were obtained by patient’s interview employing a validated questionnaire. The place of the study was in DM clinic in Farwaniyah Primary Health Care Center in Kuwait. Result: Patients with type-2 diabetes failing to initiate the prescribed insulin therapy have reported misconception regarding fear of hypoglycemia in 49% of the entire sample, pain from injections in 68% and self-blame about need for insulin i.e., sense of failure in 61% of total sample of study. Other factors were addressed like sensation by getting more severity of the disease, weight gain fear and other negative self-perceptions and attitudinal barriers were studied. Conclusion: Reducing the negative influence of psychological insulin resistance (PIR) on treatment outcomes should be a clinical priority. The position statement of the ADA and thus the EASD quotes the Committee on Quality of Health Care in America of the Institute of medicine in defining patient-centered care as an approach “to providing care that's respectful of and aware of individual patient preferences, needs, and values and ensuring that patient values guide all clinical decisions.”17 This position statement acknowledges that glycemic management in patients with T2DM has become increasingly complex and, to some extent, controversial, considering the increasing number and type of pharmacologic agents now available. I truly believe in a patient-centered approach. The patient possesses to be a neighborhood of the decision-making process. I ask all of my new patients, and that i explain every different medication that's available. I tell them about the risks and benefits of the medications, and that I allow them to decide which medication to require . T2DM consists of interventions designed to affect the physical activity levels and food intake of a private . However, current treatment recommendations now also include initiation of pharmacotherapy at the time of diagnosis, partially as a of Metformin therapy has been shown to scale back the danger of microvascular complications related to T2DM.